ReviewCardiovascular drugs and therapy2019
Cardiac Myosin-Binding Protein C-From Bench to Improved Diagnosis of Acute Myocardial Infarction.
Review in Cardiovascular drugs and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- MMP-9 Gene Ablation Preserves Ejection Fraction During "Single-Hit" Model of HFrEF.Biochemical genetics · 2026Article
- Cardiac Myosin-Binding Protein C in Suspected Acute Coronary Syndrome: From Sarcomeric Injury Biology to Decision-Grade Risk Stratification.International journal of molecular sciences · 2026Review
- Preparation of Optical-Based Sensors for the Determination of Cardiac Myosin-Binding Protein C.ACS omega · 2026Article
- Prognostic value of point-of-care testing for cardiac myosin-binding protein C in early risk assessment of acute myocardial infarction: a prospective cohort study.Scientific reports · 2026Article
- Cardiac myosin-binding protein C: potential early biomarker of myocardial injury in coronary artery bypass surgery.Journal of cardiothoracic surgery · 2026Article
- Body-Wide Expression Profiles of Commonly Assessed Cardiac Biomarkers in a Large Cohort of Human Tissue Donors.Cardiology · 2026Article
- Complementary insights into novel biomarkers for acute myocardial infarction: reinforcing the role of a multimarker strategy.Journal of thoracic disease · 2025Article
- Cardiac myosin-binding protein-C levels are associated with severity and prognosis in stable coronary artery disease.Scientific reports · 2025Article
- Prognostic value of combining cardiac myosin-binding protein C and N-terminal pro-B-type natriuretic peptide in patients without acute coronary syndrome treated at medical cardiac intensive care units.Heart and vessels · 2025Article
- Diagnostic and Prognostic Evaluation of Novel Biomarkers Compared to ESC 0/1 h and 0/3 h Algorithms in Patients with Suspected Non-ST-Elevation Myocardial Infarction.Journal of clinical medicine · 2025Article
- Beyond troponins: Emerging diagnostic significance of novel markers in NSTEMI.Global cardiology science & practice · 2024Article
- Reference values and biological determinants for cardiac myosin-binding protein C concentrations assessed with an enzyme-linked immunosorbent assay.Journal of medical biochemistry · 2023Article
- Cardiovascular disease risk prediction in scleroderma.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Serum myosin-binding protein c levels: a new marker for exclusion of preterm birth?Turkish journal of medical sciences · 2023Article
- Contraction pressure analysis using optical imaging in normal and MYBPC3-mutated hiPSC-derived cardiomyocytes grown on matrices with tunable stiffness.Biomaterials and biosystems · 2022Article
- Cardiac myosin-binding protein C as a biomarker of acute myocardial infarction.European heart journal. Acute cardiovascular care · 2021Article
- Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction-Promises and Challenges.Diagnostics (Basel, Switzerland) · 2021Review
- The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies.International journal of molecular sciences · 2021Review
- Diagnostic and Prognostic Biomarkers for Myocardial Infarction.Frontiers in cardiovascular medicine · 2020Review
- The Biomarkers for Acute Myocardial Infarction and Heart Failure.BioMed research international · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chest pain is responsible for 6-10% of all presentations to acute healthcare providers. Triage is inherently difficult and heavily reliant on the quantification of cardiac Troponin (cTn), as a minority of patients with an ultimate diagnosis of acute myocardial infarction (AMI) present with clear diagnostic features such as ST-elevation on the electrocardiogram. Owing to slow release and disappearance of cTn, many patients require repeat blood testing or present with stable but elevated concentrations of the best available biomarker and are thus caught at the interplay of sensitivity and specificity.We identified cardiac myosin-binding protein C (cMyC) in coronary venous effluent and developed a high-sensitivity assay by producing an array of monoclonal antibodies and choosing an ideal pair based on affinity and epitope maps. Compared to high-sensitivity cardiac Troponin (hs-cTn), we demonstrated that cMyC appears earlier and rises faster following myocardial necrosis. In this review, we discuss discovery and structure of cMyC, as well as the migration from a comparably insensitive to a high-sensitivity assay facilitating first clinical studies. This assay was subsequently used to describe relative abundance of the protein, compare sensitivity to two high-sensitivity cTn assays and test diagnostic performance in over 1900 patients presenting with chest pain and suspected AMI. A standout feature was cMyC's ability to more effectively triage patients. This distinction is likely related to the documented greater abundance and more rapid release profile, which could significantly improve the early triage of patients with suspected AMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.